UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 398

Sortiert nach

Acute myeloid leukaemia

The Lancet (British edition), 2023-06, Vol.401 (10393), p.2073-2086

2023

Volltextzugriff (PDF)

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

Blood, 2015-02, Vol.125 (9), p.1367-1376

2015

Volltextzugriff (PDF)

In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia

PloS one, 2016-12, Vol.11 (12), p.e0166891

2016

Volltextzugriff (PDF)

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

The New England journal of medicine, 2019-10, Vol.381 (18), p.1728-1740

2019

Volltextzugriff (PDF)

Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy

Leukemia research, 2015-02, Vol.39 (2), p.183-191

Erba, Harry P

2015

Volltextzugriff (PDF)

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML

The New England journal of medicine, 2018-06, Vol.378 (25), p.2386-2398

2018

Volltextzugriff (PDF)

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

Blood, 2013-06, Vol.121 (24), p.4854-4860

2013

Volltextzugriff (PDF)

Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC)

American journal of clinical pathology, 2020-12, Vol.154 (6), p.731-741

2020

Volltextzugriff (PDF)

Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Blood, 2022-07, Vol.140 (2), p.112-120

2022

Volltextzugriff (PDF)

Pevonedistat (MLN4924), a First‐in‐Class NEDD8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study

British journal of haematology, 2015-05, Vol.169 (4), p.534-543

2015

Volltextzugriff (PDF)

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

Journal of clinical oncology, 2017-08, Vol.35 (24), p.2745-2753

2017

Volltextzugriff (PDF)

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML

Blood, 2018-03, Vol.131 (13), p.1415-1424

2018

Volltextzugriff (PDF)

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

The lancet oncology, 2015-09, Vol.16 (9), p.1025-1036

2015

Volltextzugriff (PDF)

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia

Blood, 2018-01, Vol.131 (4), p.387-396

2018

Volltextzugriff (PDF)

Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905

Journal of clinical oncology, 2014-04, Vol.32 (12), p.1242-1248

2014

Volltextzugriff (PDF)

Shifting paradigms in the treatment of older adults with AML

Seminars in hematology, 2019-04, Vol.56 (2), p.110-117

2019

Volltextzugriff (PDF)

Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia

Haematologica (Roma), 2024-02, Vol.109 (2), p.401

2024

Volltextzugriff (PDF)

SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia

Journal of clinical oncology, 2022-05, Vol.40 (14), p.1574-1582, Article 1574

2022

Volltextzugriff (PDF)

Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: Importance of achieving treatment‐free remission

American journal of hematology, 2015-03, Vol.90 (3), p.242-249

Erba, Harry P.

2015

Volltextzugriff (PDF)

Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203

Leukemia, 2024-07, Vol.38 (7), p.1488-1493

2024

Volltextzugriff (PDF)

Improved outcomes with "7+3" induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data

Haematologica (Roma), 2023-01, Vol.108 (1), p.42

2023

Volltextzugriff (PDF)

Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network

Haematologica (Roma), 2023-11, Vol.108 (11), p.3148

2023

Volltextzugriff (PDF)

1 – 25 von 398

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(383)
Mit Volltextzugriff
(368)

Publikationsform

Sprache

Englisch
(398)
Japanisch
(19)

Erscheinungsjahr

n.n

Thema

Humans
(128)
Science & Technology
(127)
Life Sciences & Biomedicine
(124)
Hematology
(83)
Aged
(72)
Female
(70)
Male
(67)
Middle Aged
(67)
Oncology
(61)
Adult
(59)
Acute Myeloid Leukemia
(55)
Leukemia, Myeloid, Acute - Drug Therapy
(50)
Aged, 80 And Over
(43)
Treatment Outcome
(43)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(29)
Leukemia
(29)
Prognosis
(29)
Leukemia, Myeloid, Acute - Genetics
(27)
Remission Induction
(26)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(24)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Acute myeloid leukaemia

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC)

Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Pevonedistat (MLN4924), a First‐in‐Class NEDD8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML

Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia

Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905

Shifting paradigms in the treatment of older adults with AML

Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia

SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia

Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: Importance of achieving treatment‐free remission

Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203

Improved outcomes with "7+3" induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data

Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network

Suchergebnisse filtern